Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.

@article{Hoffman2008CarbamoylphosphonateMM,
  title={Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.},
  author={A. Hoffman and Bashir Qadri and Julia Frant and Yiffat Katz and S. R. Bhusare and E. Breuer and R. Hadar and R. Reich},
  journal={Journal of medicinal chemistry},
  year={2008},
  volume={51 5},
  pages={
          1406-14
        }
}
  • A. Hoffman, Bashir Qadri, +5 authors R. Reich
  • Published 2008
  • Chemistry, Medicine
  • Journal of medicinal chemistry
    • cis-2-Aminocyclohexylcarbamoylphosphonic acid ( cis-ACCP) was evaluated in vitro and in two in vivo cancer metastasis models. It reduced metastasis formation in mice by approximately 90% when administered by a repetitive once daily dosing regimen of 50 mg/kg via oral or intraperitoneal routes and was nontoxic up to 500 mg/kg, following intraperitoneal administration daily for two weeks. Pharmacokinetic investigation of cis-ACCP in rats revealed distribution restricted into the extracellular… CONTINUE READING
    View on PubMed
    doi.org
    33 Citations
    Highly Influencial Citations
    2
    Background Citations
    9
    33 Citations
    Citation Type

    Citation Type

    Orally Active, Antimetastatic, Nontoxic Diphenyl Ether‐Derived Carbamoylphosphonate Matrix Metalloproteinase Inhibitors
    • 12
    Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment.
    • 16
    N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
    • 30
    Synthesis of Enantiomeric Aminoalkylcarbamoylphosphonates and Their Evaluation as Dual-Action Anticancer MMP and Carbonic Anhydrase Inhibitors
    • 3
    Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells.
    • 5
    Dual targeting of cancer-related human matrix metalloproteinases and carbonic anhydrases by chiral N-(biarylsulfonyl)-phosphonic acids
    • 5
    • PDF
    Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.
    • 24
    Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
    • 65
    The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
    • 31
    • PDF
    Glyco-Phospho-Glycero Ether Lipids (GPGEL): synthesis and evaluation as small conductance Ca2+-activated K+ channel (SK3) inhibitors
    • 12
    • PDF

    References

    SHOWING 1-10 OF 31 REFERENCES
    Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.
    • 35
    Carbamoylphosphonate Matrix Metalloproteinase Inhibitors 3: In vivo Evaluation of Cyclopentylcarbamoylphosphonic Acid in Experimental Metastasis and Angiogenesis
    • 21
    • PDF
    Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group
    • 41
    Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form.
    • 37
    A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas
    • 37
    Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
    • M. Rudek, W. Figg, +7 authors E. Reed
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2001
    • 148
    Carbamoylphosphonate MMP inhibitors. Part 4: The influence of chirality and geometrical isomerism on the potency and selectivity of inhibition
    • 14
    Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
    • 947
    The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors.
    • 167
    Recent non-hydroxamate matrix metalloproteinase inhibitors
    • 53